The combination of ibrutinib, spleen tyrosine kinase inhibitor R406, and HDAC inhibitor vorinostat increased apoptosis of MCL cells, which correlated with activation of caspase-3 and poly-(ADP-ribose) polymerase cleavage. Here, HDAC9 is linked to mantle cell lymphoma.